The Federal Drug Administration today approved a new drug designed to fight the affects of the interchange cap on financial services executives.
"This is a breakthrough in designer drugs that is safe and effective in alleviating angst, anxiety and fear among a targeted group of potential sufferers," said April Firstwater, a spokesman for the FDA. "What really impressed us, and caused us to fast-track approval, was the drug's ability to allow the user to see the upside of a 12 cent per transaction fee."
The new drug, called DurbinEez, was developed and is manufactured by B. Wary Pharma. Rare but serious side effects include hot flashes, decreased earnings and an overwhelming desire to hug an NCUA examiner.
Complete your profile to continue reading and get FREE access to CUTimes.com, part of your ALM digital membership.
Your access to unlimited CUTimes.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical CUTimes.com information including comprehensive product and service provider listings via the Marketplace Directory, CU Careers, resources from industry leaders, webcasts, and breaking news, analysis and more with our informative Newsletters.
- Exclusive discounts on ALM and CU Times events.
- Access to other award-winning ALM websites including Law.com and GlobeSt.com.
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
